I thought about the shelving issue as well, but there are too many indications for any BP to not invest further into it. Most of the legwork is done already and with a proven safety profile, it would be a no-brainer to invest a bit more to develop leronlimab vs. continuing down a more risky path with new or even drugs currently under development. It all comes down to a business decision: which option has bigger ROI?

And I get it that there is a discount to the share price....hence my snarky comment about greedy mfers.